Evidence map›Paper›PMID 34625602›Full record

ArticleScientific reports2021

Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.

Chie Miyabe, Yupeng Dong, Takaharu Ikeda, Kazuo Takahashi, Yoshishige Miyabe, Tamihiro Kawakami

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chie MiyabeDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. cmderma.ak@twmu.ac.jp.
Yupeng DongDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takaharu IkedaDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Kazuo TakahashiDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Yoshishige MiyabeDepartment of Cell Biology, Institute for Advanced Medical Sciences, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Tamihiro KawakamiDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Tohoku Medical and Pharmaceutical University · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysfunction of immunoinhibitory signals and persistent T cell activation reportedly play important roles in the development of vasculitis. The skin is one of the most accessible organs, and it is suitable for the characterization of immune cell signatures. However, the inhibitory checkpoint molecules in the skin and their relevance to vasculitis have not been studied. Here, we investigated the profile of immune checkpoint molecules in the skin and peripheral blood of patients with vasculitis and healthy donors. We found that some of the inhibitory checkpoint molecules, including programmed cell death 1 receptor (PD-1), were elevated in T-cells in the blood of patients with systemic and cutaneous vasculitis. In addition, programmed death-ligand 1 (PD-L1) expression was elevated in the skin of patients with cutaneous vasculitis. Histologically, PD-L1 was highly expressed in the vessels in the skin along with CD4

Indexed as

B7-H1 AntigenBiomarkersProgrammed Cell Death 1 ReceptorAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansLymphocyte ActivationMaleMiddle AgedSkinVasculitisB7-H1 AntigenBiomarkersProgrammed Cell Death 1 Receptor

Identifiers

PMID34625602
PMCPMC8501116
OpenAlexW3202010755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.